Mangostene xanthone

Other Names

8-deoxygartaninalpha-mangostinalpha-mangostin (α-mangostin)beta-mangostinbeta-mangostin (β-mangostin)gamma-mangostingamma-mangostin (γ-mangostin)Garcinia malaccensis Hook.f.Garcinia mangostana L.Garcinia mangostana pericarp extractgarcinone Cgarcinone Dgarcinone Egartaninmăng cụtmanggismanggistanmanggustanmangistanmangkutmangostánmangostanMangostana garcinia Gaertn.mangostanomangostãomangosteenmangosteen pericarp extractmangostinmangostingonemangostinsmangoustannormangostinoxygenated xanthoneprenylated xanthoneprenylated xanthonespurple mangosteenqueen of fruitssmeathxanthone Atovophyllin Atricyclic isoprenylated polyphenolxanthone glycosidexanthonoidxanthonoidsxanthonolignoidмангостанมังคุด山竹

Synopsis

Mangosteen Xanthones (Garcinia mangostana L.): A Comprehensive Reference

1. Identity: Botanical Origin, Chemical Names, and Preparations

1.1 Botanical Source and Nomenclature

Mangosteen (Garcinia mangostana L.) is a tropical tree native to Southeast Asia that produces a fruit whose pericarp contains a family of tricyclic isoprenylated polyphenols referred to as xanthones. The species belongs to the family Clusiaceae and is native to Southeast Asia; its fruits possess a distinctive and pleasant taste that has granted them the epithet of "queen of the fruits." It is cultivated in the tropical rainforest of several Southeast Asian nations including Indonesia, Malaysia, Sri Lanka, the Philippines, and Thailand.

The term "mangosteen xanthone" (sometimes spelled "mangostene xanthone" in supplement labeling) refers collectively to the family of oxygenated polycyclic compounds produced by this plant. Xanthones are oxyheterocyclic ketones that can be classified into five subgroups: simple oxygenated xanthones, prenylated xanthones, xanthonolignoids, xanthone glycosides, and miscellaneous.

1.2 Chemical Identity

Xanthones have a unique chemical structure composed of a tricyclic aromatic system (C6–C3–C6), with isoprene, methoxyl, and hydroxyl groups located at various positions on the A and B rings, resulting in a diverse array of xanthone compounds. Xanthones are found in only a select few higher plant families. At least 68 distinct xanthones have been identified in different parts of the G. mangostana plant, with 50 being present in the fruit's pericarp at higher concentrations than in the aril or edible portion of the fruit. The most abundant xanthones in the pericarp are α-mangostin and γ-mangostin.

Other xanthones identified in mangosteen pericarp include β-mangostin, gartanin, 8-deoxygartanin, garcinones A, B, C, D and E, mangostinone, 9-hydroxycalabaxanthone, and isomangostin, among others. In 1994, several antioxidant xanthone constituents of mangosteen extracts were identified as α-mangostin and γ-mangostin together with epicatechin and procyanidins A2 and B2, using a ferric thiocyanate method.

1.3 Common Forms and Preparations

The seeds and pericarps of the fruit have a long history of use in the traditional medicinal practices of the region, and beverages containing mangosteen pulp and pericarps are sold worldwide as nutritional supplements. Commercial preparations include whole-fruit juice or puree beverages, standardized pericarp (rind) extracts in capsule or tablet form, and powdered pericarp preparations. Formulations including teas, ointments, tinctures, and other preparations have been used in traditional Eastern medicine. In research settings, the pericarp extract is most frequently studied, as the pericarp is the primary site of xanthone concentration. Some supplement products are standardized to a defined percentage of total xanthones, with α-mangostin commonly used as the marker compound.

2. Traditional and Historical Use

2.1 Southeast Asian Traditions

The mangosteen plant has been grown for millennia and is native to the rainforests of Southeast Asia. People in countries such as Indonesia, Malaysia, Sri Lanka, the Philippines, and Thailand have used the pericarp (peel, rind, hull, or ripe fruit) of Garcinia mangostana as a traditional medicine for the treatment of abdominal pain, diarrhea, dysentery, infected wounds, suppuration, and chronic ulcers.

For over two hundred years, infusions and decoctions made from mangosteen peels and seeds have been used in traditional medicine to treat skin diseases, gastrointestinal and urinary tract infections, as well as to provide laxative, fever-reducing, and scurvy-preventing effects.

2.2 Ayurvedic and Broader Regional Use

α-Mangostin is a xanthone present in the pericarp of Garcinia mangostana Linn., which is mentioned in Ayurveda and is a widely used functional food supplement. In Southeast Asia, mangosteen has been considered a medicinal plant and has been used to treat skin infections, wounds, dysentery, various urinary disorders, cystitis, gonorrhea, suppuration, and chronic ulcers.

2.3 Ecological Role of Xanthones in the Plant

The mangosteen plant uses xanthones and tannins to promote an astringent effect against invading insects and fungi. This defensive biosynthetic origin helps explain the broad antimicrobial and antifungal properties documented across laboratory studies.

3. Key Constituents and Active Compounds

3.1 α-Mangostin

α-Mangostin is the most extensively studied xanthone in mangosteen. α-Mangostin, the most abundant xanthone isolated from the mangosteen, has received substantial attention as it has proven to be a potent phytochemical, specifically as an anticancer agent, in numerous different cancer cell studies and cancer animal models. α-Mangostin, a bioactive xanthone derived from the Garcinia mangostana L. Clusiaceae fruit, has demonstrated significant anti-inflammatory and immunomodulatory properties.

3.2 γ-Mangostin

The xanthones α- and γ-mangostin are major bioactive compounds found in mangosteen that are reported to have anti-inflammatory and antioxidant properties. γ-Mangostin has also been particularly noted for its activity at histamine H1 and serotonergic receptors, and for COX-inhibitory activity in neurological cell models. Unlike α-mangostin, which exhibits relatively poor penetration of the blood–brain barrier, gartanin, garcinone C, and γ-mangostin are much more permeable, though much less prevalent.

3.3 β-Mangostin and Minor Xanthones

The pericarp of mangosteen is a rich source of xanthones including α-mangostin, β-mangostin, and γ-mangostin. Among the minor compounds, gartanin and 8-deoxygartanin have shown antioxidant and peroxynitrite-scavenging activities. Bioactivity-guided fractionation of the pericarp, using a peroxynitrite-scavenging assay, led to five active xanthones — 8-hydroxyxanthone, gartanin, α-mangostin, γ-mangostin, and smeathxanthone A — with IC₅₀ values below 10 μM.

3.4 Non-Xanthone Constituents

Mangosteen pericarp also contains epicatechin and procyanidins A2 and B2, as well as tannins and anthocyanins in the aril. The fruit is rich in phenolic compounds such as xanthones, anthocyanins, and phenolic acids. While xanthones are the principal and most pharmacologically investigated class, the overall biological activity of whole pericarp preparations may reflect contributions from multiple compound classes.

4. Established Mechanisms of Action

4.1 Anti-Inflammatory Mechanisms

α-Mangostin exerts its anti-inflammatory effects through the suppression of pro-inflammatory cytokines, modulation of immune cell activity, and inhibition of key signaling pathways such as nuclear factor-kappa B (NF-κB) and mitogen-activated protein kinase (MAPK).

Molecular docking studies have identified α-mangostin binding to NF-κB and COX proteins, and in LPS-induced macrophage models it has been shown to inhibit cytokine production, prevent NF-κB nuclear translocation, and inhibit COX-1 and COX-2 enzymes. In silico modelling showed that α-mangostin has the lowest binding energy with COX-2 and NF-κB proteins. It has been found to inhibit the production of PGE₂ and nitric oxide and iNOS protein expression. TNF-α and IL-6 cytokines were inhibited significantly (p < 0.05) at 8 and 14 μg/mL concentration, and at higher doses it inhibits NF-κB translocation together with suppressing COX-2, but not COX-1.

Pretreating intestinal epithelial cells with α-mangostin at 2.5, 5, and 10 μM caused a dose-dependent decrease in LPS-induced cytokines — including NO, PGE₂, IL-6, TNFα, and IL-1β — and also dose-dependently inhibited LPS-induced mRNA expressions of iNOS, COX-2, and TLR4 signaling components. These results suggest that α-mangostin suppresses pro-inflammatory cytokine release through inhibiting the activation of TLR4-mediated TAK1–NF-κB signaling pathways.

In human macrophage and adipocyte models, α- and γ-mangostin attenuated LPS-induced expression of inflammatory genes including TNF-α, IL-6, and IP-10 in a dose-dependent manner, attenuated LPS-activated MAPK and AP-1, with γ-mangostin also reducing NF-κB; and the ability of macrophage-conditioned media to cause inflammation and insulin resistance in human adipocytes was attenuated by pretreatment with γ-mangostin.

In bone marrow-derived mast cell models, α- and γ-mangostins inhibited IL-6, prostaglandin D₂, and leukotriene C₄ production, as well as degranulation, and were found to repress COX-2 expression, suggesting utility in alleviating mast cell-mediated allergic inflammatory responses.

4.2 Antioxidant Mechanisms

Excess of reactive oxygen species and reactive nitrogen species has been found to be linked to various diseases including cancer, cardiovascular disorders, diabetes mellitus, inflammation, and neurodegenerative diseases. As a typical polyphenol, the beneficial effects of xanthones on inflammation are believed to result partly from antioxidative activities, and downregulation of oxidative stress-sensitive pathways such as COX-2, NF-κB, and MAPKs is responsible for reduced inflammatory reactions. Mangosteen xanthones have been demonstrated to scavenge DPPH, ABTS, and peroxynitrite radicals in laboratory models.

4.3 Pro-Apoptotic and Anticancer Mechanisms

α-Mangostin induces apoptosis through both intrinsic and extrinsic pathways, modulating key cellular processes implicated in cancer progression. It causes mitochondrial dysfunction, activates caspases, and regulates autophagy, endoplasmic reticulum stress, and oxidative stress. The ability of α-mangostin to inhibit cell proliferation, modulate cell cycle progression, and induce apoptosis is linked to its effects on key signaling pathways including Akt, NF-κB, and p53.

In hepatocellular carcinoma (HCC) cells, α-mangostin reduces cell viability in a dose- and time-dependent manner; α-mangostin-mediated apoptosis is accompanied by nuclear chromatin condensation and cell cycle arrest in the sub-G1 phase, as well as phosphatidylserine exposure, and triggers the mitochondrial caspase apoptotic pathway via loss of mitochondrial membrane potential, release of cytochrome c, and regulation of Bcl-2 family member expression.

α-Mangostin has been found to induce apoptosis through activation of the intrinsic pathway following the downregulation of signaling cascades involving MAP kinases and the serine/threonine kinase Akt.

4.4 Enzyme and Receptor Modulation

Some xanthones from mangosteen have been found to influence specific enzyme activities, such as aromatase, HIV-1 protease, inhibitor κB kinase, quinone reductase, sphingomyelinase, topoisomerase, and several protein kinases, and they also modulate histamine H1 and 5-hydroxytryptamine 2A (5-HT2A) receptor binding. Alpha-, beta-, and gamma-mangostin are purported to be selective serotonin type 2A (5-HT2A) antagonists.

Additionally, α-mangostin exhibits immunomodulatory properties by influencing both innate and adaptive immune responses, affecting macrophage polarization, T cell differentiation, and cytokine production.

5. Scientific Evidence by Area of Health

5.1 Antioxidant Activity — Human Clinical Evidence

Evidence strength: Moderate (small RCTs; effects on biomarkers, not clinical outcomes).

A randomized, double-blind, placebo-controlled clinical trial investigated the absorption and antioxidant effects of a xanthone-rich mangosteen liquid (59 mL containing mangosteen, aloe vera, green tea, and multivitamins) in healthy human volunteers. Results indicated that α-mangostin was bioavailable, with observed C_max at t_max of around 1 hour, and the antioxidant capacity measured by ORAC assay was increased with a maximum effect of 18% after 2 hours, with the increased antioxidant level lasting at least 4 hours.

In a separate 30-day randomized, double-blind, placebo-controlled trial, the group given a mangosteen-based drink formula showed 15% more antioxidant capacity in the bloodstream than the placebo group. The same study reported that mangosteen significantly decreased the level of C-reactive protein (CRP), an indicator of systemic inflammation. After the 30-day consumption of the beverage, there were no side effects on human hepatic and kidney functions, and the mangosteen-based formula significantly increased antioxidant capacity and possessed anti-inflammatory benefits with no side effects on immune, hepatic, and renal functions for long-term consumption.

These human antioxidant trials, while randomized and placebo-controlled, are limited by small sample sizes, mixed-ingredient products (making xanthone-specific attribution difficult), and measurement of surrogate biomarkers rather than clinical disease endpoints.

5.2 Anti-Inflammatory Activity — Human Clinical Evidence

Evidence strength: Preliminary (small RCTs and pilot studies; biomarker-level outcomes).

In a multi-centered RCT involving 104 patients diagnosed with gingivitis or incipient periodontitis, participants were randomly allocated to either a daily capsule containing 194 mg of a mangosteen and propolis extract complex (MAEC) for eight weeks, or placebo. There was a significant difference in the modified gingival index at four and eight weeks between the test and control groups; in the test group, crevicular IL-6 was reduced after eight weeks.

The human anti-inflammatory data are largely derived from biomarker studies or studies involving combination products. No large, well-powered randomized controlled trials have examined mangosteen xanthones as a standalone anti-inflammatory therapy for a defined inflammatory disease condition.

5.3 Anticancer Activity

Evidence strength: Preclinical only (in vitro and animal models); no completed human clinical trials as of current literature.

Xanthones unique to the mangosteen have been reported to display significant anti-cancer and anti-tumor activities, specifically through the promotion of apoptosis, targeting of specific cancer-related proteins, or modulation of cell signaling pathways. Research has examined α-mangostin's activity across various cancer types including colon cancer, glioblastoma, melanoma, oral squamous cell carcinoma, and pancreatic cancer.

In tongue mucoepidermoid carcinoma (YD-15) cells, α-mangostin induced apoptosis: MTT assays showed that cell proliferation decreased significantly in a dose-dependent manner; DAPI staining illustrated chromatin condensation at 15 μM; and flow cytometric analysis showed that α-mangostin suppressed cell viability by inducing apoptosis and promoting cell cycle arrest in the sub-G1 phase.

Despite recent advancements in the treatment of prostate cancer, therapeutic resistance driven by the AR-V7 splice variant remains a significant challenge; mechanistic studies reveal that α-mangostin induces degradation of both AR, AR mutant, and AR-V7, potentially helping to overcome therapeutic resistance.

Recent in vitro research in leukemia, glioblastoma, and melanoma cell lines has shown promise for α-mangostin as a subject for further study. Moreover, α-mangostin exhibits synergistic effects with conventional chemotherapeutic agents, suggesting its potential utility in combination therapies. Preclinical studies highlight the safety profile of α-mangostin, demonstrating significant tumor growth inhibition without adverse effects on normal cells; however, future clinical investigations are warranted to explore its clinical utility and efficacy in cancer prevention and therapy.

All anticancer evidence to date is derived from cell-line and animal studies. No completed human clinical trials have evaluated mangosteen xanthones as a cancer treatment or preventive in humans.

5.4 Metabolic Effects: Insulin Resistance, Obesity, and Diabetes

Evidence strength: Promising but preliminary (one small human pilot RCT; supporting animal and cell data).

A pilot prospective RCT evaluated the safety and efficacy of mangosteen extract on insulin resistance, weight management, and inflammatory status in obese female patients with insulin resistance. Twenty-two patients were randomized 1:1 to behavioral therapy alone or behavioral therapy and mangosteen; 20 completed the 26-week study. The mangosteen group reported a significant improvement in insulin sensitivity (HOMA-IR −53.22% vs. −15.23%, p = 0.004), and no side effect attributable to treatment was reported. The authors suggested a possible supplementary role of mangosteen extracts in the treatment of obesity, insulin resistance, and inflammation.

Xanthones from mangosteen and their physiological effects — including antiobesity, antihyperglycemic, antidyslipidemia, antidiabetic, and anti-inflammatory effects — have been demonstrated in experimental studies to have beneficial effects on obesity, diabetes, hyperglycemia, dyslipidemia, and inflammatory states. However, the volume of human data remains very limited; the insulin sensitization pilot study had a small sample size and an all-female population, limiting generalizability.

5.5 Neurological and Psychiatric Applications

Evidence strength: Emerging; one published RCT for bipolar depression (mixed results), supported by preclinical data for neurodegenerative diseases.

Research to date demonstrates that the neurobiological properties of mangosteen pericarp are well aligned with the current understanding of the pathophysiology of bipolar disorder and schizophrenia. Mangosteen pericarp has antioxidant, putative neuroprotective, anti-inflammatory, and putative mitochondrial-enhancing properties, with animal studies demonstrating favorable pharmacotherapeutic benefits with respect to these disorders.

In a proof-of-concept randomized controlled trial for bipolar depression, participants received 24 weeks of either 1,000 mg mangosteen pericarp or placebo per day in addition to usual treatment. The primary outcome was change in severity of mood symptoms measured by the Montgomery–Åsberg Depression Rating Scale (MADRS). This study was noted to have several limitations, including small sample size and participants with mild depression at baseline. Nevertheless, it is the only clinical study that directly evaluates the potential therapeutic value of mangosteen pericarp in the treatment of a serious mental illness accompanied by depression.

Preclinical data indicate that mangosteen-derived agents target specific disease pathologies such as amyloid beta production and deposition as well as cholinergic dysfunction in Alzheimer's disease (AD); α-synuclein aggregation in Parkinson's disease (PD); and modulation of monoamine disturbance in depression. Mangosteen pericarp extract and its bioactive xanthones are considered promising candidates for the treatment of AD, PD, and depression; however, further clinical trials are essential to decipher their efficacy and pharmacokinetic and safety profiles in these disorders.

5.6 Oral Health

Evidence strength: Preliminary (one multi-center RCT; combination product).

α-Mangostin compounds exhibit anti-inflammatory activity by inhibiting the production of nitrous oxide, TNF-α, and interleukin-8. A randomized clinical trial using local delivery of 4% mangostana gel into the periodontal pockets of chronic periodontitis patients showed significant improvement in periodontal parameters.

5.7 Antimicrobial Activity

Evidence strength: Preclinical only (in vitro; no human clinical data).

The major secondary metabolites of mangosteen, the xanthones, exhibit a variety of biological activities including antibacterial, antifungal, antiinflammatory, antioxidant, antiplasmodial, and cytotoxic activities. In vitro research has documented activity against Staphylococcus aureus (including MRSA strains), Mycobacterium tuberculosis, and various fungi. All antimicrobial findings to date are from laboratory models; no human clinical trials have established efficacy for any infectious disease indication.

6. Bioavailability and Pharmacokinetics

Like many polyphenolic compounds, xanthones from mangosteen have limited oral bioavailability due to poor aqueous solubility, extensive first-pass metabolism, and rapid phase II conjugation (glucuronidation and sulfation) in the liver and intestine.

The first report on xanthone bioaccessibility and metabolism was performed using the coupled in vitro digestion/Caco-2 human intestinal cell model. Optimal bioaccessibility of α- and γ-mangostin was dependent on incorporation into bile salt mixed micelles. In addition, α-mangostin was transported across the apical surface of enterocyte-like Caco-2 cells and partially converted to phase II metabolites.

A human study investigated the absorption and antioxidant effects of a xanthone-rich mangosteen liquid in healthy volunteers after acute consumption of 59 mL. Results indicated that α-mangostin was bioavailable, with observed C_max at t_max of around 1 hour, and the ORAC antioxidant capacity was increased by a maximum of 18% after 2 hours, with the increased antioxidant level lasting at least 4 hours.

The vast majority of studies have focused on the anti-cancer and anti-inflammatory activities of α-mangostin. Work from multiple groups has shown that α-mangostin and other xanthones are metabolized by both human and animal cells, meaning that the possibility of metabolites exerting some of the observed effects cannot be ruled out. More pharmacokinetic studies are needed to assess the bioavailability of xanthones from mangosteen-containing beverages and food products.

7. Dosage Forms and Reported Dosages from Studies

The following dosages are cited only as reported in the identified peer-reviewed sources and do not represent clinical recommendations.

Acute single-dose human bioavailability study: 59 mL of a xanthone-rich mangosteen liquid (containing mangosteen, aloe vera, green tea, and multivitamins) in healthy volunteers.
30-day randomized controlled trial: 60 participants assigned to a mangosteen-based drink formula consumed daily for 30 days.
Bipolar depression proof-of-concept RCT: 1,000 mg mangosteen pericarp or placebo per day for 24 weeks, in addition to usual treatment.
Gingivitis/periodontitis RCT: a single daily capsule containing 194 mg of a mangosteen and propolis extract complex for eight weeks.
Insulin resistance pilot RCT: 22 patients over 26 weeks; mangosteen extract administered alongside behavioral therapy (specific per-dose amount not extracted from available abstract).
In vitro anti-inflammatory concentrations: α-mangostin at 2.5, 5, and 10 μM demonstrated dose-dependent cytokine inhibition in intestinal epithelial cell models.

8. Body Systems Associated with Mangosteen Xanthone Research

The main phytochemicals present in the species are isoprenylated xanthones, a class of secondary metabolites with multiple reports of biological effects, including antioxidant, pro-apoptotic, anti-proliferative, antinociceptive, anti-inflammatory, neuroprotective, hypoglycemic, and anti-obesity actions. Based on published research, the body systems most associated with mangosteen xanthone investigation include:

Immune system and inflammation: NF-κB, MAPK, COX-2 pathway modulation; cytokine suppression across multiple cell types.
Oncology / cell biology: Pro-apoptotic and antiproliferative activity studied in breast, colon, prostate, liver, cervical, glioblastoma, and other cancer cell lines.
Metabolic system: Insulin sensitization, antidiabetic effects, antiobesity mechanisms including pancreatic lipase inhibition.
Central nervous system: Neuroprotection, anti-neuroinflammation, monoamine modulation, amyloid-beta and α-synuclein pathology in preclinical disease models.
Oral health / periodontal: Antibacterial and anti-inflammatory applications for gingivitis and periodontitis.
Gastrointestinal system: Traditional use for diarrhea and dysentery; modern interest in gut microbiota modulation.
Integumentary (skin): Traditional use for wound healing and skin infections; emerging research in antimicrobial topical applications.

9. Safety Considerations and Known Interactions

9.1 Overall Safety Signal from Human Studies

Available clinical trial data from a 30-day mangosteen beverage RCT indicated no side effects on human hepatic and kidney functions, and no side effects on immune, hepatic, or renal functions were identified for the duration of the trial. Collectively, findings from published studies indicate positive safety profiles of mangosteen-based products in humans; however, most studies have investigated the safety of mangosteen fruit-based beverages, not mangosteen pericarp-derived products directly.

9.2 Lactic Acidosis — Case Report

A case of severe lactic acidosis was described in association with the use of mangosteen juice as a dietary supplement in the United States (published in the American Journal of Kidney Diseases, 2008). However, no cause-effect relationship was determined, mainly because mangosteen was not the single constituent administered in this case. This remains the only published case report of a severe adverse event associated with mangosteen supplementation in the peer-reviewed literature.

9.3 Limited Long-Term Toxicity Data

Controlled intervention trials of the efficacy of xanthones in human volunteers, as well as characterization of the absorption, metabolism, and elimination of these compounds, remain quite limited. Also, the potential toxicity of chronic ingestion of formulations containing mangosteen pericarp and its extracts has received minimal attention.

9.4 Receptor Interactions and Drug Pharmacology

Mangosteen xanthones have been found to influence aromatase, HIV-1 protease, inhibitor κB kinase, quinone reductase, sphingomyelinase, topoisomerase, and several protein kinases, and to modulate histamine H1 and 5-HT2A receptor binding. These receptor-level activities suggest the theoretical possibility of pharmacodynamic interactions with drugs acting on these same targets (e.g., antihistamines, antipsychotics with 5-HT2A activity). However, no formal drug interaction trials in humans have been published.

9.5 Bioavailability and Metabolic Considerations

Pharmacokinetic studies in rats demonstrated low systemic bioavailability of α-mangostin following oral dosing, with extensive metabolism to conjugated metabolites. The formation of phase II metabolites (glucuronides and sulfates) by intestinal and hepatic enzymes means that active parent xanthones may circulate at lower concentrations than expected from in vitro studies, which could complicate extrapolation of preclinical findings to human therapeutic outcomes.

9.6 Evidence Gaps and the State of Clinical Evidence

Despite numerous health claims on advertising sites for producers and retailers of products and beverages containing mangosteen, there is insufficient scientific evidence at this time to support the use of mangosteen-containing supplements as enhancers of health and useful adjuvants for the treatment of various pathophysiological illnesses. Controlled intervention trials of the efficacy of xanthones in human volunteers, as well as characterization of absorption, metabolism, and elimination of these compounds, remain quite limited.

Despite consistently impressive preclinical findings across anticancer, neuroprotective, antidiabetic, and anti-inflammatory research, almost no well-designed clinical trials have confirmed therapeutic benefits for any condition in humans.

References

Health Conditions

Health conditions that Mangostene xanthone may help support.

No conditions available.

Body Systems

Body systems that Mangostene xanthone may help support.

No body systems available.